每周一次生长激素再扩适应症!诺和诺德Sogroya®获批用于ISS、SGA及努南综合征儿童

药渡Daily
Mar 01

近日,诺和诺德今日宣布,美国食品药品监督管理局已批准其每周一次的长效生长激素Sogroya®(somapacitan-beco)新增三项儿童适应症,用于治疗2.5岁及以上患有特发性矮小、出生时孕周小且2岁时无追赶生长,或与努南综合征相关的生长失败的儿童。此次批准使Sogroya成为长效生长激素中获批适应症最广泛的产品,覆盖从生长激素缺乏到多种非GHD身材矮小病因的儿童患者群体。一、突破每日注射困局...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10